We are progressing our development programs and anticipate reaching new milestones in 2023
Short Bowel Syndrome with Intestinal Failure
- 18,000 people are estimated to suffer from Short Bowel Syndrome with Intestinal Failure (SBS-IF) in the U.S., Europe and Japan
- Apraglutide has completed phase 2 studies and is currently being evaluated in a pivotal phase 3 clinical trial
- The global Phase 3 clinical, called STARS (Study of Apraglutide in SBS) is evaluating the safety and efficacy of apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF)
Primary Biliary Cholangitis (PBC)
- PBC affects an estimated 130,000 people in the U.S.2
- COUR is currently conducting a clinical study with early data assessing T-cell response from patients enrolled expected in the second half of 2023, which we believe will inform timing of topline data and potential option exercise for this program
- Introduces a potentially new game-changing therapy for PBC patients in significant need of new treatment options
Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)
- IC/BPS affects an estimated 4-12 million people in the U.S.3
- Continuing Phase 2 proof of concept study in IC/BPS
- Study designed to evaluate the potential impact of IW-3300 on chronic visceral pain in patients with IC/BPS
Strengthening Our Leading GI Portfolio
In June 2023, we expanded our pipeline through the acquisition of VectivBio to include apraglutide, an investigational GLP-2 analog being evaluated as a potential once-weekly treatment for patients with Short Bowel Syndrome with intestinal failure (SBS-IF).
SBS-IF is a severe malabsorptive condition requiring ongoing I.V. administration of fluids and nutrients and is associated with significant morbidity and mortality, high economic burden, and an impaired quality of life. A substantial number of SBS-IF patients remain dependent on chronic parenteral support, and there is considerable unmet need in this patient population, which has an estimated addressable population of 18,000 adult patients across the U.S., Europe, and Japan
In November 2021 into a collaboration and license option agreement with COUR Pharmaceuticals Development Company, Inc., which grants us an option to acquire an exclusive license to research, develop, manufacture and commercialize, in the U.S., products containing CNP-104, a potential treatment for PBC, a rare autoimmune disease targeting the liver that affects an estimated 130,000 people in the U.S. according to a study published in Gastroenterology. Currently, there is no approved therapy that addresses the root cause of the autoimmune destruction of the bile ducts in PBC. In December 2021, COUR received U.S. Fast Track Designation. The proof-of-concept study is ongoing, and given the strong science underlying this therapy, we plan to assess T-cell response in patients dosed with CNP-104 in the second half of 2023, which will inform the timing of topline data.
We are developing our wholly owned IW-3300 – a GC-C agonist - for the potential treatment of visceral pain conditions, such as interstitial cystitis/bladder pain syndrome (IC/BPS) and endometriosis. IC/BPS affects an estimated 4 to 12 million Americans, according to the Interstitial Cystitis Association. An estimated 4 million reproductive-age women in the U.S. have been diagnosed with endometriosis, according to a study published in Gynecologic and Obstetric Investigation. Both diseases have a limited number of treatment options available. In 2022, we successfully completed dosing studies in healthy volunteers, and are currently executing the proof-of-concept study in IC/BPS. IC/BPS patients are being screened, dosed and site activations are going very well.
Collaboration is a core value and critical to our success.